MedTrace Logo

Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction

NCT07263711 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-12-04

No results posted yet for this study

Summary

The goal of this clinical study is to learn if an artificial intelligence (AI) model can accurately predict important molecular changes in gliomas, a type of brain tumor, using digital pathology images.

The main questions this study aims to answer are:

How accurate is the AI model in predicting key molecular alterations compared with standard molecular testing? Can the AI model shorten the time needed for diagnosis and reduce the need for expensive molecular tests?

Researchers will collect whole slide images from multiple hospitals and use the AI model to predict molecular results. The predictions will be compared with the actual test results from standard laboratory methods.

Participants will:

Allow the use of their pathology images and molecular test results for research.

Have no additional treatments or procedures beyond standard medical care.

This study will help determine whether AI-assisted tools can provide faster and lower-cost molecular diagnosis for glioma, improving patient care and supporting equal access to precision medicine.

Conditions

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • LI LIANG · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2030-09-01
Completion
2030-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07263711 on ClinicalTrials.gov